Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's Perspective.
Sheean ME, Naumann-Winter F, Capovilla G, Kalland ME, Malikova E, Mariz S, Matusevicius D, Nistico R, Schwarzer-Daum B, Tsigkos S, Tzogani K, Larsson K, Magrelli A, Stoyanova-Beninska V. Sheean ME, et al. Among authors: matusevicius d. Front Med (Lausanne). 2021 Aug 27;8:744625. doi: 10.3389/fmed.2021.744625. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34513895 Free PMC article.
The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products.
Palomo GM, Pose-Boirazian T, Naumann-Winter F, Costa E, Duarte DM, Kalland ME, Malikova E, Matusevicius D, Vitezic D, Larsson K, Magrelli A, Stoyanova-Beninska V, Mariz S. Palomo GM, et al. Among authors: matusevicius d. Mol Ther. 2023 Dec 6;31(12):3414-3423. doi: 10.1016/j.ymthe.2023.09.020. Epub 2023 Oct 4. Mol Ther. 2023. PMID: 37794679 Free article.
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation.
Kalland ME, Pose-Boirazian T, Palomo GM, Naumann-Winter F, Costa E, Matusevicius D, Duarte DM, Malikova E, Vitezic D, Larsson K, Magrelli A, Stoyanova-Beninska V, Mariz S. Kalland ME, et al. Among authors: matusevicius d. Gene Ther. 2024 Mar 14. doi: 10.1038/s41434-024-00446-0. Online ahead of print. Gene Ther. 2024. PMID: 38480914
Biomarkers for Alzheimer's disease therapeutic trials.
Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B; Oxford Task Force Group. Hampel H, et al. Prog Neurobiol. 2011 Dec;95(4):579-93. doi: 10.1016/j.pneurobio.2010.11.005. Epub 2010 Dec 2. Prog Neurobiol. 2011. PMID: 21130138 Review.
Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellström S, Marko-Varga G, Végvári A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M, Olsson T. Ottervald J, et al. Among authors: matusevicius d. J Proteomics. 2010 Apr 18;73(6):1117-32. doi: 10.1016/j.jprot.2010.01.004. Epub 2010 Jan 20. J Proteomics. 2010. PMID: 20093204
Monocyte-derived cytokines in multiple sclerosis.
Filion LG, Graziani-Bowering G, Matusevicius D, Freedman MS. Filion LG, et al. Among authors: matusevicius d. Clin Exp Immunol. 2003 Feb;131(2):324-34. doi: 10.1046/j.1365-2249.2003.02053.x. Clin Exp Immunol. 2003. PMID: 12562396 Free PMC article.
Altered expression of costimulatory molecules in myasthenia gravis.
Teleshova N, Matusevicius D, Kivisäkk P, Mustafa M, Pirskanen R, Link H. Teleshova N, et al. Among authors: matusevicius d. Muscle Nerve. 2000 Jun;23(6):946-53. doi: 10.1002/(sici)1097-4598(200006)23:6<946::aid-mus16>3.0.co;2-4. Muscle Nerve. 2000. PMID: 10842273
27 results